Anti-CTLA-4 antibody binds to CTLA-4 on activated T cells and prevents T cell inactivation in lymph nodes during the initial stage of cancer-immunity cycles, while anti-PD-1/PD-L1 antibodies inhibit T cell inactivation in tumor tissue during the effector phase. Here, PDCD1 is linked to cancer.